The Cost of Us Pharmaceutical Price Reductions: A Financial Simulation Model of R&D Decisions

36 Pages Posted: 8 Mar 2005

See all articles by Thomas A. Abbott

Thomas A. Abbott

Thomson-Medstat

John A. Vernon

University of North Carolina (UNC) at Chapel Hill; National Bureau of Economic Research (NBER)

Date Written: February 2005

Abstract

Previous empirical studies that have examined the links between pharmaceutical price controls, profits, cash flows, and investment in research and development (R&D) have been largely based on retrospective statistical analyses of firm- and/or industry-level data. These studies, which have contributed numerous insights and findings to the literature, relied upon ad hoc reduced-form model specifications. In the current paper we take a very different approach: a prospective micro-simulation approach. Using Monte Carlo techniques we model how future price controls in the U.S. will impact early-stage product development decisions in the pharmaceutical industry. This is done within the context of a net present value (NPV) framework that appropriately reflects the uncertainty associated with R&D project technical success, development costs, and future revenues. Using partial-information estimators calibrated with the most contemporary clinical and economic data available, we demonstrate how pharmaceutical price controls will significantly diminish the incentives to undertake early-stage R&D investment. For example, we estimate that cutting prices by 40 to 50 percent in the U.S. will lead to between 30 to 60 percent fewer R&D projects being undertaken (in early-stage development). Given the recent legislative efforts to control prescription drug prices in the U.S., and the likelihood that price controls will prevail as a result, it is important to better understand the firm response to such a regulatory change.

Suggested Citation

Abbott, Thomas A. and Vernon, John A., The Cost of Us Pharmaceutical Price Reductions: A Financial Simulation Model of R&D Decisions (February 2005). NBER Working Paper No. w11114, Available at SSRN: https://ssrn.com/abstract=661786

Thomas A. Abbott

Thomson-Medstat ( email )

777 E. Eisenhower Parkway
Ann Arbor, MI 48108
United States

John A. Vernon (Contact Author)

University of North Carolina (UNC) at Chapel Hill ( email )

102 Ridge Road
Chapel Hill, NC NC 27514
United States

National Bureau of Economic Research (NBER)

1050 Massachusetts Avenue
Cambridge, MA 02138
United States

Here is the Coronavirus
related research on SSRN

Paper statistics

Downloads
159
Abstract Views
1,746
rank
205,452
PlumX Metrics